Chidozie Ugwumba Sells 5,556 Shares of Clene (NASDAQ:CLNN) Stock

Posted by Hanz Christensen on Jan 25th, 2026

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 5,556 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $5.27, for a total transaction of $29,280.12. Following the sale, the insider directly owned 599,603 shares in the company, valued at $3,159,907.81. The trade was a 0.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The shares were sold at an average price of $5.32, for a total transaction of $67,377.80.
On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total transaction of $61,200.95.
On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The shares were sold at an average price of $4.80, for a total transaction of $59,673.60.
On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The stock was sold at an average price of $5.13, for a total transaction of $40,644.99.
On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The stock was sold at an average price of $5.10, for a total transaction of $64,071.30.
On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The shares were sold at an average price of $5.12, for a total value of $100,459.52.
On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The shares were sold at an average price of $4.89, for a total value of $127,653.45.
On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total value of $179,877.50.
On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $56,900.25.
On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The shares were sold at an average price of $6.09, for a total value of $19,457.55.

Clene Price Performance

Shares of CLNN stock opened at $5.31 on Friday. The company has a market cap of $57.61 million, a price-to-earnings ratio of -1.57 and a beta of 0.87. The stock has a 50 day simple moving average of $6.75 and a 200-day simple moving average of $6.51. Clene Inc. has a 1-year low of $2.28 and a 1-year high of $13.50.

Clene (NASDAQ:CLNN – Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. Analysts anticipate that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CLNN shares. D. Boral Capital restated a “buy” rating and set a $23.00 price target on shares of Clene in a research report on Friday, January 9th. UBS Group reissued a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. Finally, Benchmark reiterated a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Clene presently has an average rating of “Moderate Buy” and an average target price of $32.60.

Get Our Latest Report on CLNN

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp acquired a new stake in shares of Clene in the third quarter valued at approximately $29,000. Jane Street Group LLC purchased a new stake in Clene in the 2nd quarter valued at $47,000. Lunt Capital Management Inc. increased its stake in shares of Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after acquiring an additional 21,217 shares during the last quarter. Finally, Scoggin Management LP raised its holdings in shares of Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after acquiring an additional 42,750 shares during the period. 23.28% of the stock is currently owned by institutional investors and hedge funds.

Clene Company Profile

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).